Physician profile
Logan Hill
NPI 1932797248
$1,024.44
in general payments reported to CMS, 2019-2025
23 companies · $496 in 2025
The $496 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $194 · 2023: $258 · 2024: $76.24 · 2025: $496.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $830.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $830.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $181.26 | 2025 | Interstim |
| Boehringer Ingelheim Pharmaceuticals, INC. | $94.43 | 2022-2024 | Jardiance, Stiolto Respimat, Spiriva Respimat |
| Lilly USA, LLC | $85.20 | 2022 | |
| Janssen Biotech, INC. | $71.85 | 2025 | Erleada |
| Endo USA, INC. | $62.98 | 2025 | Xiaflex, Aveed |
| Pfizer INC. | $60.34 | 2023-2025 | |
| Boston Scientific Corporation | $51.80 | 2023 | Moses 550 D\F\L |
| Accord Healthcare, INC. | $46.01 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $41.59 | 2024 | Airsupra, Farxiga |
| Novo Nordisk INC | $36.20 | 2024-2025 | Ozempic, Rybelsus |
| Blue Earth Diagnostics | $32.76 | 2025 | Posluma |
| E.R. Squibb & Sons, L.L.C. | $32.44 | 2023 | Eliquis |
| Janssen Pharmaceuticals, INC | $26.37 | 2022-2023 | Spravato |
| Exeltis, USA INC. | $24.68 | 2022 | |
| Exact Sciences Corporation | $23.11 | 2023 | Cologuard Collection Kit |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $21.78 | 2025 | |
| Abbvie INC. | $20.86 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $20.27 | 2022 | |
| Alnylam Pharmaceuticals INC. | $19.90 | 2023 | Onpattro |
| Merck Sharp & Dohme LLC | $18.71 | 2025 | |
| Mylan Specialty L.P. | $18.54 | 2022 | |
| Glaxosmithkline, LLC. | $17.66 | 2025 | Arexvy, Shingrix |
| Idorsia Pharmaceuticals US INC | $15.70 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Logan Hill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.